[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]

Area of Science:

• Cardiovascular Research
• Pharmacology
• Aging Biology

Background:

• Age-related aortic arteriosclerosis and stiffening lack specific treatments.
• Anti-inflammatory ligands for peroxisome proliferator-activated receptor-gamma show arterial benefits in atherosclerosis.
• The study explores pioglitazone's protective effects against vascular wall disease.

Purpose of the Study:

• Investigate pioglitazone's efficacy in preventing arteriosclerosis and its consequences.
• Evaluate pioglitazone's impact on aortic wall rigidity, pulse pressure, and left ventricular hypertrophy.
• Assess pioglitazone's anti-inflammatory and anti-calcification effects in a rat model.

Main Methods:

• Utilized a rat model of elastocalcinotic arteriosclerosis (hypervitaminosis D and nicotine).
• Administered chronic pioglitazone treatment to VDN rats.
• Assessed medial calcification, inflammatory markers (TNF-alpha, IL-1B), elastic fiber integrity, aortic stiffness, pulse pressure, and left ventricular hypertrophy.

Main Results:

• Pioglitazone decreased TNF-alpha and IL-1B mRNA expression in VDN rats.
• The treatment blunted aortic wall calcification and prevented elastic fiber fragmentation.
• Pioglitazone significantly reduced aortic wall stiffness, aortic pulse pressure, and left ventricular hypertrophy.

Conclusions:

• Pioglitazone demonstrates protective effects against elastocalcinotic arteriosclerosis in a rat model.
• The drug mitigates key pathological features including inflammation, calcification, and aortic stiffening.
• Findings suggest potential clinical relevance for elderly patients with aortic stiffening and isolated systolic hypertension.